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A B S T R A C T
Purpose
Expression of erbB2 and/or epidermal growth factor receptor (EGFR) is associated with biologic
aggressiveness and poor prognosis in malignant salivary gland tumors (MSGTs). This phase II
study was conducted to determine the antitumor activity of lapatinib, a dual inhibitor of EGFR and
erbB2 tyrosine kinase activity, in MSGTs.
Patients and Methods
Patients with progressive, recurrent, or metastatic adenoid cystic carcinoma (ACC) immunohisto-
chemically expressing at least 1 EGFR and/or 2 erbB2 were treated with lapatinib 1,500 mg
daily, in a two-stage cohort. Patients with non-ACC MSGTs were treated as a separate
single-stage cohort.
Results
Of 62 patients screened, 29 of 33 (88%) ACC and 28 of 29 (97%) non-ACC patients expressed
EGFR and/or erbB2. Forty patients with progressive disease were enrolled onto the study.
Among 19 assessable ACC patients, there were no objective responses, 15 patients (79%)
had stable disease (SD), nine patients (47%) had SD  6 months, and four patients (21%) had
progressive disease (PD). For 17 assessable non-ACC patients, there were no objective
responses, eight patients (47%) had SD, four patients (24%) had SD  6 months, and nine
patients (53%) had PD. The most frequent adverse events were grade 1 to 2 diarrhea, fatigue,
and rash. Eight paired tumor biopsies for correlative studies were procured; results did not
correlate with clinical outcome.
Conclusion
Although no responses were observed, lapatinib was well tolerated, with prolonged tumor
stabilization of  6 months in 36% (95% CI, 21% to 54%) of assessable patients. The antitumor
effects of lapatinib in MGSTs appear mainly cytostatic, hence evaluation of other molecular
targeted agents, or combinations with lapatinib, may be considered. Continued efforts should be
made to gain better understanding into the biology of this heterogeneous group of malignancies.
J Clin Oncol 25:3978-3984. © 2007 by American Society of Clinical Oncology
INTRODUCTION
Malignant salivary gland tumors (MSGTs) account
for less than 1% of all cancers, and 6% to 7% of
cancers of the head and neck.1-3 Adenoid cystic car-
cinoma histology (ACC) accounts for 11% and 41%
of major and minor MSGTs, respectively. ACC is
treated mainly with surgery and radiation; systemic
therapy is reserved for the management of local re-
currence no longer amenable to additional local
therapy, and in the palliation of symptoms from
metastases. Response rates to conventional chemo-
therapy are generally low, based on small institu-
tional series, and are not clearly associated with
any survival advantage.4,5 Unlike ACC, non-ACC
MSGTs are a heterogeneous group with distinct his-
tologies and variable biologic behavior. Patients
with recurrent or metastatic non-ACC MSGTs may
achieve objective response rates ranging from 15%
to 50% with conventional cytotoxic chemotherapy,
but duration of response is typically limited to 6 to 9
months.4,5 Given this, patients with progressive
ACC and non-ACC MSGT are ideal candidates for
trials of investigational new drugs.
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Lapatinib is a dual inhibitor of the tyrosine kinase domains of the
epidermal growth factor receptor (EGFR) and erbB2 by interfering
with adenosine triphosphate binding, thus blocking autophosphory-
lation and resultant downstream signaling activities, including cellular
proliferation and survival.6 In head and neck squamous cell cancers,
EGFR expression predicts for poor disease-free and cause-specific
survivals.7 Overexpression of erbB2 is associated with biologic aggres-
siveness and poor prognosis in MSGTs.8-13 Clinicopathologic studies
with limited sample sizes examining the expression of EGFR and
erbB2 in MSGTs by immunohistochemistry (IHC) have reported
wide variations in frequencies ranging from 0% to 85%14-18 and 0% to
100%,10,12,16,19-30 respectively.
This study aimed to evaluate the antitumor activity of lapatinib in
recurrent and/or metastatic ACC and other MSGTs with documented
IHC expression of EGFR and/or erbB2. We chose to study ACC and
non-ACC MSGTs because of the paucity of effective palliative treat-
ments available to both groups and the evidence for target expression
in both histologic subtypes by IHC.
PATIENTS AND METHODS
Patient Eligibility
Patients  18 years of age with histologically or cytologically confirmed
ACC or non-ACC MSGTs were potentially eligible if they had  1 EGFR
and/or  2 erbB2 expressing tumors, determined by IHC. Patients were
required have recurrent and/or metastatic disease not amenable to potentially
curative surgery or radiotherapy, and documented disease progression within
6 months of study entry. Progressive disease (PD) was defined as a minimum
of 20% increase in the sum of maximal diameters of measurable disease, the
appearance of new lesions, or deterioration in clinical status. Patients were
required to have measurable disease according to the Response Evaluation
Criteria in Solid Tumors Committee (RECIST) criteria,31 and may have had
unlimited prior therapy up to 4 weeks before study enrollment. Other key
eligibility criteria included Eastern Cooperative Oncology Group performance
status  2; life expectancy of at least 12 weeks; normal organ and marrow
function (total bilirubin within normal limits, AST and ALT  2.5 upper
limit of normal, creatinine within normal limits or creatinine clearance  60
mL/min/1.73 m2, leukocytes  3,000/L, absolute neutrophil count  1,500/
L, and platelets  100,000/L); and normal cardiac left ventricular ejection
fraction (LVEF) by multiple-gated acquisition scan. Patients were required to
undergo tumor biopsy once before (between days 7 and 0) and once during
investigational therapy (between days 14 and 21) unless there was a medical
contraindication. Patients were excluded if they had prior treatment with an
EGFR or erbB2 inhibitor. Participants provided written informed consent
before study enrollment; the study was approved by all local research ethics
committees of participating centers.
Study Therapy and Dose Modifications
Study treatment consisted of lapatinib 1,500 mg orally once daily on an
empty stomach. Lapatinib was supplied by the National Cancer Institute,
Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation
Program. Cycle length was 28 days and treatment was continued until disease
progression, unacceptable toxicity, patient refusal, or physician’s decision to
withdraw the patient. Patients were assessed for objective response, classified
by RECIST,31 every 8 weeks.
Toxicity was graded according to National Cancer Institute Common
Terminology Criteria for Adverse Events, version 3.0. For intolerable grade 2
or for grade 3 or 4 toxicity, lapatinib was withheld until the toxicity was grade
 1 and then resumed at 1,500 mg/d for the first intolerable grade 2 toxicity, or
1,000 mg/d for subsequent intolerable grade 2 toxicity and any grade 3 or 4
toxicity. A second dose reduction to 750 mg/d was allowed. Necessity for a
third dose reduction, persistent toxicity after 3 weeks off lapatinib, grade 3 or 4
interstitial pneumonitis, or left ventricular systolic dysfunction would man-
date discontinuation of study therapy.
Archival Specimens
Histologies of all patients were reviewed centrally by a blinded patholo-
gist (M.T.). Two (5%) discrepancies were identified when compared with
original pathology reports.
Screening for EGFR and erbB2 expression, using archival paraffin sam-
ples or fresh tumor biopsies, was measured by IHC. For EGFR, IHC was
performed using a standard avidin-biotin technique. The incubation time was
1 hour with the primary mouse monoclonal antibody (clone 31G7, 1:50
dilution; Zymed Laboratories, South San Francisco, CA). For erbB2, the sec-
tions were subjected to antigen retrieval by boiling in citrate buffer followed by
incubation with the primary antibody (rabbit antip185/HER-2, Herceptest;
DAKO AS, Copenhagen, Denmark). After sections were washed, they were
incubated for 20 minutes each with biotinylated secondary antibody, followed
by streptavidin–horseradish peroxidase using the Multi-Species Ultra Strepta-
vidin Kit (Signet Laboratories, Dedham, MA). The slides were developed for 5
minutes using the NovaRed substrate kit (Vector Laboratories, Burlingame,
CA), and then counterstained with Mayer’s hematoxylin. Slides were scored
on a 0 to 3 scale: 0, staining in less than 10% of tumor cells or no staining; 1,
faint and partial membrane staining in  10% of tumor cells; 2, weak to
moderate complete membrane staining in  10% of tumor cells; or 3,
moderate to strong complete membrane staining in  10% of tumor cells.
Correlative Studies on Paired Tumor Specimens
Biomarkers related to EGFR and erbB2 and their associated pathways
were analyzed in tumor tissues using a colorimetric IHC technique. Phosphor-
ylation of EGFR activates downstream signaling pathways that include Ras-
Raf–mitogen-activated protein kinase kinase extracellular signal-regulated
kinase (ERK), phosphatidylinositol 3-kinase/Akt, and the signal transducer
and activator of transcription-3 (STAT-3) pathways. Ki-67 is an index of
cellular proliferation, p27 is a cell cycle regulatory protein, and insulin-like
growth factor receptor-1 (IGFR-1) and STAT-3 are signaling proteins poten-
tially involved in resistance to inhibition of the EGFR/erbB2 pathway. Phos-
phorylation denotes the activation state of the cellular phosphoproteins
under evaluation. Paired tumor biopsies were assessed by IHC for EGFR,
phosphorylated (p) -EGFR, erbB2, p-erbB2, p-ERK, p-Akt, p27, Ki-67,
IGFR-1, and p-STAT-3.
Frozen samples were embedded in Cryomatrix embedding resin
(Thermo Shandon, Pittsburgh, PA) and 5-m sections were prepared using a
cryostat. Fixation, permeabilization, and staining for specific antigens were
performed, as described previously.32 Because of a lack of staining with frozen
samples for p-EGFR, p-erbB2, and p-Akt, the samples were fixed in formalin
and processed into paraffin blocks to retest for these three markers. Primary
antibodies used for IHC are listed in Appendix Table A1 (online only).
Scoring was done similar to the archival specimens stained for EGFR and
erbB2. For p27, cytoplasmic and nuclear staining was scored separately. p-ERK
scoring was based on the percentage of tumor cells positive for cytoplasmic
staining. Both Ki-67 and p-STAT-3 scoring were based on the percentage of
tumor cells positive for nuclear staining.
Statistical Considerations
The primary objective of this study was to determine the objective re-
sponse rate (complete responses and partial responses [PRs]) of lapatinib in
ACC. Secondary objectives were to evaluate the duration of response; rate and
duration of stable disease (SD); progression-free, median, and overall survival
(OS) rates; and safety and tolerability of lapatinib in this population. A two-
stage design was used for the ACC cohort, according to Simon.33 The null
hypothesis assumed that the response rate was less than 5% and the alternative
hypothesis assumed that the response rate was at least 20%. The design allowed
enrollment of 12 assessable patients in the first stage. If one response was
observed, an additional 25 assessable patients were to be enrolled. Assessment
of the activity of lapatinib in non-ACC MSGTs was exploratory without a
predetermined study design, with up to 30 patients planned.
For correlative samples, descriptive statistics were used to summarize
each marker outcome at pretreatment, during treatment, and any difference
between the two. Wilcoxon signed rank test was used to assess statistically
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significant changes in marker value from pre- to during-treatment biopsy.
Fisher’s exact tests assessed whether pretreatment marker values, or the change
in marker value, predicted SD as best response. For this analysis, optimal splits
of the marker were performed to maximize statistical power. Whisker plots
and bar graphs were used to demonstrate marker values pre- and during-
treatment. Cox proportional hazards regression methods assessed whether
pretreatment marker values, or change in markers, were predictive of time to
progression (TTP). No investigation of predictors of OS was conducted. All
tests were two sided and exact P values are reported throughout.
RESULTS
Patients and Treatment
Between November 2004 and March 2006, 20 patients with ACC
and 20 patients with non-ACC MSGTs were enrolled at seven centers
in Canada and the United States. Fifty-seven (92%) of 62 screened
patients were positive for EGFR and/or erbB2. Of the 57 patients, nine
were found to be ineligible for the study and eight patients declined
participation. Of 40 patients enrolled onto the study, 39 and 36 were
assessable for toxicity and objective response, respectively. One non-
ACC patient had rapidly progressive disease after enrollment, never
received study drug, and was excluded from additional analysis. Three
patients, one with ACC and two with non-ACC, were not assessable
for response but were included in the toxicity analysis; one had evi-
dence of brain metastasis within 7 days of starting study treatment,
one had a prior active malignancy within 5 years of study entry (and
was ineligible per protocol), and one was withdrawn from study after
7 days to be treated with a protocol-prohibited medication (proton
pump inhibitor). Patient characteristics are listed in Table 1.
Response and Survival
Of 19 assessable ACC patients, four had PD within two cycles. Of
the 15 patients with SD after two cycles of treatment, six patients
experienced disease progression within four cycles, and seven patients
experienced disease progression after 6, 7, 10, 13, 14, 20, and 21 cycles,
respectively. For the remaining two patients, one patient with SD was
removed from study after six cycles due to an asymptomatic decrease
in LVEF, and one remains on treatment and has received 21 cycles
of therapy.
Of 17 assessable non-ACC MSGT patients, one died at the end of
cycle 2 due to disease progression/pneumonia before objective re-
sponse evaluation, seven had PD within two cycles, and two with
objective SD were taken off therapy after two cycles (one for symp-
tomatic progression and one at the discretion of the local investigator).
Of seven patients with SD after two cycles, three patients experienced
disease progression before cycle 5, and four patients experienced dis-
ease progression after 6, 9, 10, and 20 cycles, respectively.
Although no objective responses were observed (Table 1), a sub-
set of patients had a reduction in measurable disease (Fig 1). When
analyzed together, 13 patients had documented SD  6 months (Ta-
ble 2). For these patients, the mean TTP before initiating therapy was
3 months, with a range of 2 to 6 months.
For all patients, the median follow-up duration, OS, and
progression-free survival (PFS) was 15.8 months, not reached, and 3.4
months (95% CI, 2.1 to 5.3 months), respectively. For ACC, the
median OS duration and 6-month OS rate were not reached and
90.0% (95% CI, 77.8% to 100%), respectively, whereas the median
PFS duration and 6-month PFS rate were 3.5 months (95% CI, 3.1 to
12.7 months) and 35.0% (95% CI, 19.3% to 63.6%) respectively. For












Male 12 60 16 84
Female 8 40 3 16
Performance status
0 8 40 10 53
1 11 55 9 47
2 1 5 0
Disease status at study entry
Locoregionally recurrent 3 15 4 21
Metastatic 15 75 13 68
Both 2 10 2 11
Histology
ACC 20 100 0
Adenocarcinoma 0 7 35
Large/salivary duct carcinoma 0 4 20
Squamous cell carcinoma 0 3 15
Undifferentiated carcinoma 0 3 15
Mucoepidermoid carcinoma 0 2 10
Acinic cell carcinoma 0 1 5
IHC results
EGFR positive/erbB2 positive 1 5 8 40
EGFR positive /erbB2 negative 19 95 12 60
EGFR-positive scores
0 0 0
1 5 25 3 15
2 10 50 6 30
3 5 25 11 55
erbB2-positive scores
0 13 65 7 35
1 6 30 5 25
2 1 5 3 15
3 0 5 25
No. of prior regimens
0 11 55 9 47
1 4 20 3 16
2 4 20 5 26
3 1 5 2 11
Prior therapy
Chemotherapy 9 45 10 53









Best response to lapatinib treatment
PR 0 0
SD  6 months 9 45 4 21
SD  6 months 6 30 4 21
PD 4 20 9 47
NA 1 5 2 11
Abbreviations: ACC, adenoid cystic carcinoma; EGFR, epidermal growth
factor receptor; IHC, immunohistochemistry; PR, partial response; SD, stable
disease; PD, progressive disease; NA, not assessable.
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non-ACC, the median OS duration and 6-month OS rate were 13.8
months (95% CI, 7.3 to not reached) and 69.3% (95% CI, 50.1% to
95.9%), respectively, whereas the median PFS duration and 6-month
PFS rate were 2.1 months (95% CI, 1.6 to 8.3 months) and 19.9%
(95% CI, 7.3% to 54.0% months), respectively (Fig 2).
Correlative Studies
Archival specimens. The percentage of assessable patients with
SD  6 months in subgroups based on EGFR or erbB2 expression in
archival specimens suggested a positive correlation as follows: 1 to
2 EGFR (seven of 23; 30%) versus 3 EGFR (six of 13; 46%); 0 to
2 erbB2 (10 of 32; 31%) versus 3 erbB2 (three of four; 75%).
Interestingly, three of three patients (100%) with 3 EGFR and 3
erbB2 staining in archival tumor specimens had SD  6 months
(Table 2).
Paired Tumor Biopsies
Pretreatment and during-treatment biopsies were taken from 22
and 16 patients, respectively. Only eight patients had sufficient tumor
cells on microscopic evaluation in both samples (Fig 3). A trend
toward decreased p-Akt, decreased Ki-67, and increased p-STAT-3
was observed, but small numbers precluded any conclusions. There
were no statistically significant associations between marker assess-
ment and clinical outcome, nor were they of predictive value.
Toxicity
Lapatinib was tolerated well by most patients (Table 3). The
majority of adverse events were grade 1 to 2 in intensity. Two grade 4
adverse events occurred: a secondary malignancy (laryngeal cancer)
and laryngeal edema. Neither was believed to be related to lapatinib.
Three patients died while on study, two as a result of disease progres-
sion, and one as a result of an intercurrent pneumonia.
Two patients with ACC had an asymptomatic reduction in LVEF
from baseline of at least 10%. One had a baseline LVEF of 76% that
decreased to 60%, 44%, and 55% after two, four, and six cycles,
respectively. A second patient had a baseline LVEF of 62% that de-
creased to 51% after two cycles; LVEF values on the subsequent 11
evaluations ranged from 54% to 65%.
DISCUSSION
Salivary gland cancers are a heterogeneous group with varied natural
history, aggressiveness, and prognosis. Given that EGFR or ErB2 status
may be linked to a poor prognosis, lapatinib, an inhibitor against these
targets, may benefit a group of patients with MSGT. Although no






































Fig 1. Maximal percentage of tumor reduction for target lesions by Response
Evaluation Criteria in Solid Tumors Committee (RECIST). Percentages are
calculated using the summed unidimensional measurements of target lesions
per RECIST.






ACC 21 2 0 3
ACC 6 1 0 3
ACC 6 3 1 3
ACC 21 3 1 3
ACC 7 2 1 3
ACC 19 1 0 6
ACC 10 2 1 2
ACC 14 2 0 4
ACC 13 3 0 3
Undifferentiated carcinoma 6 1 1 3
Adenocarcinoma 20 3 3 3
Squamous cell carcinoma 9 3 3 5
Undifferentiated carcinoma 10 3 3 6
Abbreviations: ACC, adenoid cystic carcinoma; EGFR, epidermal growth












































6 12 18 24
Fig 2. Survival and time to progression for patients with adenoid cystic carcinoma
(ACC) and non-ACC malignant salivary gland tumors treated with lapatinib.
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was observed in 13 (36%) of 36 assessable patients with PD before
starting therapy.
Recent trials of targeted therapies in patients with advanced ACC
have reported variable results. Imatinib (which inhibits the c-KIT
tyrosine kinase) and gefitinib (which inhibits the EGFR tyrosine ki-
nase) have been evaluated.34-40 Four phase II studies and two case
reports have evaluated imatinib in 45 patients with ACC. Three re-
ported responses have been documented.34,40 Although disease stabi-
lization was documented in studies of imatinib and gefitinib, disease
progression as a criterion for study entry was not typically required,
and therefore stabilization may in fact reflect the relatively indolent
natural course of the disease. The largest of these trials, reported
previously by our group,39 evaluated the use of imatinib in 16 patients.
The median TTP on that study was 2.3 months compared with 3.5
months for the ACC patients reported in the present trial. Although
direct comparisons across two different studies are not valid, they may
be of exploratory value in a rare disease such as ACC. This caveat
notwithstanding, it would seem that treatment with lapatinib may be
associated with a more prolonged TTP than treatment with imatinib.
Of note, in contrast to our prior study with imatinib, our current study
with lapatinib enrolled only patients with documented PD. Disease
stabilization may represent more meaningful biologic activity in such
a patient population.
In addition to imatinib and gefitinib, other targeted agents have
been investigated in this disease. A phase II study of trastuzumab in
patients with advanced or metastatic MSGTs confirmed one PR and
an overall median TTP of 4.2 months.41 A phase II trial of bortezomib
in patients with incurable ACC reported a median PFS of 8.5 months
in patients with PD within 9 months of study entry.42 In a phase I trial
of axitinib (AG-013736), a potent small molecule tyrosine kinase
inhibitor of all known vascular endothelial growth factor receptors,
platelet-derived growth factor receptor beta, and c-KIT, one patient
with ACC experienced a PR.43
Identifying relevant proliferation and antiapoptosis survival
pathways in malignant cells may inform therapeutic options based on
tumor biology rather than histology alone. Preclinical data have
shown the effects of lapatinib on human tumor cell lines.44 Although
inhibition of EGFR resulted preferentially in cell growth arrest, inhi-
bition of erbB2 yielded both growth arrest and cell death. In a phase I
study of lapatinib, all patients achieving PR had tumors that overex-
pressed erbB2, whereas pretreatment EGFR status did not discrimi-
nate between responders and nonresponders.45 In this regard, it is of
interest that among our patients with non-ACC MSGTs, all three
patients with 3 coexpressions of EGFR and erbB2 achieved SD  6
months. This observation may suggest greater therapeutic effect when
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Fig 3. Pretreatment (pre) and during-treatment (on) tumor biopsies from the
eight paired samples available for assessment. (A) Bar graphs illustrate marker
values for epidermal growth factor receptor (EGFR), erbB2, insulin-like growth
factor receptor-1 (IGFR-1), p27, phosphorylated (p-) erbB2, p-Akt. (B) Whisker
plots illustrate marker values for extracellular signal-regulated kinase (p-ERK),
Ki-67, and signal transducer and activator of transcription-3 (p-STAT-3). Staining
was poor for p-EGFR and thus this marker was not included in (B).

















Diarrhea 24 62 2 103 44 0
Rash (acneiform) 19 49 2 67 29 0
Fatigue 16 41 3 86 37 1
Nausea 11 28 1 52 22 0
Dry skin 8 21 1 33 14 0
Pruritus 5 13 1 31 13 0
ALT 5 13 2 17 7 0
AST 5 13 2 17 7 0
Mucositis 5 13 1 17 7 0
Hyperglycemia 5 13 2 9 4 0
Headache 4 10 3 26 11 19
Creatinine 4 10 1 13 6 0
Dysgeusia 4 10 2 13 6 0
Vomiting 4 10 2 5 2 0
Alopecia 3 8 1 25 11 0
Rash (desquamation) 3 8 2 10 4 0
Dyspepsia 3 8 2 9 4 0
Pain 3 8 2 5 2 0
Hematologic
Anemia 5 13 1 21 9 0
Leukopenia 4 10 1 6 3 0
Neutropenia 4 10 2 6 3 0
Lymphopenia 3 8 2 14 6 0
Thrombocytopenia 2 5 1 10 4 0
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patient with ACC expressed erbB2 at high levels in our study, conclu-
sions based on marker status for those patients are impossible. Despite
our desire to identify biologic pathways that might predict or correlate
with response, too few viable samples were procured. The challenge of
producing meaningful correlative study data is likely a reflection of
both technical issues and heterogeneity across patients. Most of the
patients on this study had lung metastases, for example, that are often
difficult to biopsy safely with adequate tissue acquisition. The choice of
tissue fixation is also critical in the demonstration and evaluation of
protein expression by IHC.46 Our results may have been affected
negatively by the use of fresh frozen as opposed to formalin-fixed
specimens, as others have reported previously.46
Stage I of the ACC protocol over-accrued patients because of
the overwhelming interest of investigators and patients participat-
ing in this trial. Given that no objective responses were seen in
either cohort, the second stage of the ACC arm did not open and
the non-ACC arm was also terminated. Although there were no
objective responses, a significant rate of disease stabilization seen in
a group of patients with PD at study entry is of clinical relevance.
The antitumor activity of lapatinib in MSGTs is believed to be
primarily cytostatic. With this in mind, additional evaluation of
molecular targeted therapies in this disease optimally would be
performed using a novel study design with progression-based
rather than response-based end points, as well as mandating
assessment of disease progression by RECIST within 6 months
of study entry. This study illustrates further that clinical trials in
MSGTs can accrue successfully based on collaborative efforts by
multiple groups.
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